POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.22.2021, 5:45pm CEST, WHO):   U.S. 74,227    India 15,786    Brazil 15,609    United Kingdom 51,484    Russia 37,141    Turkey 28,465    France 5,498    Iran 11,788    Argentina 1,218    Columbia 1,224    Italy 3,791    Germany 19,572    Mexico 5,069    Poland 5,716    Philippines 4,806    Ukraine 23,785    Malaysia 6,210    Peru 1,034    Netherlands 5,223    Iraq 1,882    Thailand 9,810    Czechia 3,638    Canada 2,641    Chile 1,793    Romania 15,410    Serbia 7,327    Kazakhstan 1,893    Cuba 1,435    Vietnam 3,636    Hungary 2,548    Austria 3,818    Greece 3,376    Georgia 4,155    Belarus 2,097    Bulgaria 4,816    Azerbaijan 2,005    Slovakia 3,470    Croatia 3,258    Ireland 2,026    Venezuela 1,254    Lithuania 3,016    Denmark 1,247    South Korea 1,440    Moldova 1,787    Slovenia 1,845    Armenia 2,146    Latvia 3,133    Estonia 1,323    China 51    Singapore 3,439    New Zealand 134    Australia 2,643   

Unprecedented discovery: Roche drug cocktail doubles chance of holding lung cancer at bay

Staff Writer |
Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing.

Article continues below






This is an outcome some experts on Thursday labeled unprecedented.

Thirty-seven percent of patients in Roche’s clinical trial who got Tecentriq, Avastin and chemotherapy reached the one-year mark without their cancer progressing (PFS).

For patients getting just Avastin and chemotherapy in the Impower 150 study, that fell to 18 percent.

"The study showed that people who received Tecentriq and Avastin plus chemotherapy had a 38 percent reduced risk of their disease worsening or death (progression-free survival, PFS) compared with those who received Avastin plus chemotherapy...

"Importantly, a doubling of the 12-month landmark PFS rate was observed with the combination of Tecentriq and Avastin plus chemotherapy (37 percent) compared to Avastin plus chemotherapy (18 percent)," the company said.

"The rate of tumour shrinkage (overall response rate, ORR), a secondary endpoint in the study, was higher in people treated with Tecentriq and Avastin plus chemotherapy compared with Avastin plus chemotherapy (64 percent vs. 48 percent).

"The safety profile of the Tecentriq and Avastin plus chemotherapy combination was consistent with the safety profiles of the individual medicines, and no new safety signals were identified with the combination."


What to read next

New drug to treat lung cancer in sight
Explosion of aggressive lung cancer - among nonsmokers
Additional pancreatic cancer treatments don't boost survival